Sign In
Buy ABBV
$217.07
+1.64 (+0.761%)
At Close: Jun 03, 2026
Legacy Financial Strategies LLC Sells 12,664 Shares of AbbVie Inc. $ABBV
05:05am, Monday, 09'th Feb 2026
Legacy Financial Strategies LLC lessened its position in AbbVie Inc. (NYSE: ABBV) by 66.6% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission
AbbVie's Prognosis: The February Dip Looks Like a Buy Signal
12:32pm, Thursday, 05'th Feb 2026
When the price of a high-quality stock such as AbbVie NYSE: ABBV declines after a report revealing growth, outperformance, and better-than-expected guidance, it's almost always a good time to buy.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Thursday, 05'th Feb 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
AbbVie: The Market Is Getting It Wrong
08:52am, Thursday, 05'th Feb 2026
AbbVie delivered a resilient Q4 with 10% YoY revenue growth and strong immunology performance, despite a post-earnings stock selloff. Their adjusted EPS grew 25% YoY, beating estimates, while operatin
AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot
04:25am, Thursday, 05'th Feb 2026
AbbVie has significantly outperformed prior immunology sales projections, with Skyrizi and Rinvoq now expected to reach $38 billion by 2030. ABBV's oncology and neuroscience pipelines have expanded vi
AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise
06:04pm, Wednesday, 04'th Feb 2026
AbbVie Inc. retains a Strong Buy rating, driven by a positive earnings surprise in Q4 2025, notably due to HUMIRA outperformance. Despite ongoing HUMIRA declines, ABBV demonstrates robust growth in it
AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake
05:45pm, Wednesday, 04'th Feb 2026
AbbVie Inc. has delivered strong long-term returns and maintains a >3% dividend yield, but recent Q4 earnings and guidance have tempered my near-term enthusiasm. ABBV's immunology and neuroscience div
AbbVie Inc (ABBV) Q4 2025 Earnings Call Highlights: Record Revenues and Strategic Growth Plans
04:01pm, Wednesday, 04'th Feb 2026
Adjusted Earnings Per Share (EPS): $10 for the full year, $2.71 for the fourth quarter.Total Net Revenues: $61.2 billion for the full year, $16.6 billion for t
AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)
03:39pm, Wednesday, 04'th Feb 2026
AbbVie Inc. faces investor skepticism on growth durability beyond Immunology, despite strong SKYRIZI and RINVOQ performance offsetting HUMIRA's decline. ABBV's Q4 2025 saw 18% Immunology growth and 10
AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View
01:31pm, Wednesday, 04'th Feb 2026
ABBV beats Q4 earnings and revenue estimates, but shares slip as Rinvoq and oncology sales miss expectations despite strong 2026 EPS guidance.
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
01:20pm, Wednesday, 04'th Feb 2026
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth
12:38pm, Wednesday, 04'th Feb 2026
AbbVie Inc. (NYSE: ABBV) reported fourth-quarter 2025 sales of $16.62 billion on Wednesday, beating the consensus of $16.42 billion.
AbbVie (ABBV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
11:30am, Wednesday, 04'th Feb 2026
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare
AbbVie (ABBV) Tops Q4 Earnings and Revenue Estimates
10:01am, Wednesday, 04'th Feb 2026
AbbVie (ABBV) came out with quarterly earnings of $2.71 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.16 per share a year ago.
Stock Market Today: Futures Mixed After Indexes Tumble; AMD Shares Sink; Gold Moves Back Above $5,000
09:30am, Wednesday, 04'th Feb 2026
Stock futures pointed to a mixed open Wednesday, a day after major indexes sank as technology shares sold off. Meanwhile, gold and silver futures continued to rebound after retreating from recent high
